Crescent Biopharma, Inc.（CBIO）の株式分析CBIOCrescent Biopharma, Inc.

Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications. It operates in the Healthcare sector.

Crescent Biopharma Inc is a good buy right now due to its recent positive developments and potential for growth. The stock is currently priced at $12.82, significantly lower than the analyst price target of $36, indicating a potential upside of over 180%. Additionally, the company has a strong gross margin of 100% projected for Q4 2025, which suggests high profitability on future revenue. However, investors should be cautious of the net loss of $24.8 million reported in Q2 2026, which reflects ongoing financial challenges.